Pfizer Withdraws Oxbryta, But Overall Market Impact May Be Limited

EU Regulators Recommend Suspending Approval

The withdrawal amid concerns about the risk-benefit ratio reduces treatment options for sickle cell disease, but it is not expected to have much effect on the SCD market, including the gene therapies.

• Source: Shutterstock

Less than a year ago, Pfizer Inc. was securing reimbursement in the UK for its sickle cell disease (SCD) drug, Oxbryta (voxelitor), while hematologists were debating how the increasing number of options for SCD – including Oxbryta – would fit into the treatment paradigm. Now, the URL for the drug’s website redirects to Pfizer’s announcement that it is pulling the drug from the market, while European regulators are recommending suspension of its marketing authorization there.

The New York-based drug maker said 25 September after the stock market closed that it was voluntarily withdrawing all lots...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Blood and Clotting

BioMarin’s Roctavian Continues to Shine In Hemophilia A Despite Commercial Woes

 

Roctavian shows durable bleed control and safety over five years, but high costs and access hurdles limit its commercial outlook.

Pfizer’s Hympavzi Poised For Broader Hemophilia Label

 

The drugmaker announced positive topline results for the drug in hemophilia A and B patients with inhibitors, on top of the existing approval for patients without inhibitors.

Early Blood Cancer Data Impresses As Incyte Plots Post-Jakafi Strategy

 
• By 

First results for a first-in-class mutCALR-targeted therapy in essential thrombocythemia presented at EHA point to a lucrative future for the early-stage product.

ASCO: Rusfertide Inches Toward FDA Filing With Positive 32-Week Data

 

Takeda/Protagonist are awaiting 52-week data to confirm the results from the VERIFY trial of the drug in polycythemia vera.

More from Therapy Areas

Bayer’s Kerendia Gains Blockbuster Indication For Heart Failure

 
• By 

New US approval in heart failure with preserved or mildly reduced ejection fraction should add to Kerendia’s earning power on top of chronic kidney disease indication.

Takeda Prepares Ground For Oveporexton In Narcolepsy

 

The drugmaker announced positive results from two Phase III trials for the drug in narcolepsy type 1 that analysts said bode well for the OX2R agonist class as a whole.

Phase III Success For AstraZeneca’s $5bn Hypertension Hope Baxdrostat

 

Rivals Mineralys could be first to file but AstraZeneca is banking on its cardiovascular market know-how to lead the emerging class.